BerGenBio A/S, of Bergen, Norway, secured NOK7 million (US$1.3 million) from local Sarsia Seed and Development Funds to continue its R&D activities in cancer. The firm is working on its CellSelect platform, which uses information from RNAi screening studies to identify drug targets